Linux secures USD 70mn strategic investment from ChrysCapital and Tata Capital Healthcare Fund

Linux Laboratories, one of India’s fastest-growing domestic formulations companies, has secured USD 70 million in equity capital from ChrysCapital and Tata Capital Healthcare Fund III (“TCHF III”). ChrysCapital has acquired a significant minority stake in Linux. 

The transaction comprises a combination of primary capital and secondary purchase and includes the full exit of Tata Capital Healthcare Fund II (“TCHF II”) at approximately 4x returns. Avendus Capital acted as the exclusive financial advisor to Linux on the transaction.

Founded in 2007 and headquartered in Chennai, Linux is a specialty-focused domestic formulations platform with a portfolio of over 125 brands spanning ~400 SKUs. Linux has established a leadership position in central nervous system (CNS) therapies, covering epilepsy, neuropathic pain, depression and autism, and has extended into dermatology, cardio-diabetics and nutraceuticals. Linux reaches over 60,000 doctors through a field force of more than 1,000 medical representatives across seven divisions, with a pan-India presence and a deliberate focus on specialists.

Linux has combined organic brand-building with a disciplined acquisition track record, having integrated and scaled the Biomedica and Indiabulls Pharmaceuticals portfolios alongside brands acquired from Cipla and Dr. Reddy’s Laboratories. The Company also operates its own WHO-GMP certified manufacturing facility, which supports backward integration for the branded business while anchoring a growing contract development and manufacturing (CDMO) operation and an export presence across countries.

The proceeds will support Linux’s next phase of growth, including deepening its presence in core specialties, entry into adjacent therapeutic areas, continued brand acquisitions, and further investment in manufacturing and R&D capabilities. India’s branded formulations market continues to attract strong investor interest, driven by the rising burden of chronic and sub-chronic conditions and the growing share of specialty-led, prescriber-facing portfolios.

S Ananda Kumar, Co-Founder and Executive Director, Linux said, “Linux was built on the conviction that a focused, science-led portfolio with affordability and access to quality healthcare can compete with the largest players in Indian pharma. ChrysCapital and Tata Capital Healthcare Fund III bring the sector experience and capital to take that conviction into a much larger business, and we thank TCHF II for five years of partnership on the journey so far”.

P Hariharan, Co-Founder and Executive Director, Linux said, “Our growth has come from earning the trust of specialists, one therapy at a time. With over 125 brands and a field force of more than 1,400, we now have the reach to scale proven brands, enter new therapies and new geographies considerably faster than before”.

K Keerthivasan, Co-Founder and Executive Director, Linux said, “Alongside our growth, we remain committed to strengthening our manufacturing, quality systems, R&D, technology and people. This capital marks an important milestone, enabling us to expand our capacity and scale our business. We see strong opportunities in international markets and are focussed on building new partnerships and expanding our global presence. This journey would not have been possible without the dedication and contribution of our Linuxians, customers, partners, investors, family and everyone who have supported us along the way. I sincerely thank each and every one of them. We look forward to continuing this journey together and creating new opportunities for growth”.

Kshitij Sheth, Managing Director, ChrysCapital Advisors, said, “ChrysCapital is excited to partner with Linux during the next phase of its growth and is deeply impressed by its specialty-focused franchise, rigorous execution, and M&A track record. This investment aligns with ChrysCapital’s strategy of backing fast-growing domestic formulations companies focused on chronic therapies and led by dynamic entrepreneurs. ChrysCapital looks forward to leveraging its rich experience in the sector to help Linux become a leading player in the Indian pharmaceutical market”.

Dr Jagriti Gupta, Senior Vice President, ChrysCapital Advisors, added, “Linux has built a rare combination of depth in CNS, a specialist-focused field force reaching over 60,000 doctors, and its own WHO-GMP manufacturing base. This gives the Company a strong platform to scale its existing brands and extend into adjacent therapies. ChrysCapital looks forward to working closely with the founders and the Linux team to build an enduring specialty pharma franchise”.

Visalakshi Chandramouli, Managing Partner, Tata Capital Healthcare Fund said, “Linux has been an exemplary partnership for TCHF. The founders, Dr. P Hariharan, K Keerthivasan and S Ananda Kumar, have combined deep industry expertise with entrepreneurial ambition and a strong execution culture to build Linux into a fast-growing pan-India, multi-therapy platform. Our successful exit from TCHF II is a testament to the substantial value created during this period. At the same time, our decision to reinvest through TCHF III reflects our continued conviction in the founders, the management team, and Linux’s long-term growth potential. We are delighted to continue our partnership with Linux as it embarks on its next phase of expansion and value creation.”

The post Linux secures USD 70mn strategic investment from ChrysCapital and Tata Capital Healthcare Fund appeared first on Express Pharma.